聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察

目的评价聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法使用聚乙二醇干扰素α-2a(派罗欣)联合利巴韦林(800~1200mg/d)治疗58例慢性丙型肝炎患者,疗程48周,分别于治疗12周、24周和48周及治疗结束后24周评价疗效,并观察药物副作用。结果基因1型和非基因1型患者早期应答率分别为57.1%和76.7%(P>0.05),持续应答率分别为53.6%和80.0%(P<0.05);HCV RNA高水平组和低水平组之间持续应答率分别为56.3%和80.8%,具有显著性差异(P<0.05)。结论在慢性丙型肝炎患者的治疗中,基因1型患者疗效低于非基因1型,HCV RNA低水平组的疗效优于高水平组。

Observation on the efficacy of peginterferon and ribavirin in the treatment of patients with chronic hepatitis C

Objective To evaluate the clinical effects of combination of peginterferon and ribavirin in the treatment of patients with chronic hepatitis C.Method 58 patients with chronic hepatitis C received a combination of Pagasys(180μg/week)and ribavirin(800~1200mg/d)for 48 weeks.Liver function and level of HCV RNA were determined at the 12th,24th and 48th week during the treatment.Result The early virological response(EVR)rates and sustained virological response(SVR)rates in patients with genotype 1 were 57.1% and 53.6%,but in genotype non-1 patients those were 76.7% and 80%,respectively(P<0.05);the early virological responserate in patients with high serum HCV RNA level was 56.3%,much lower than 80.8%(P<0.05)in patients with low serum HCV RNA level.Conclusion The response to the combination treatment in patients with chronic hepatitis C is influenced by genotype and the serum level of HCV RNA.